These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20712585)

  • 21. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer.
    Guppy A; Jamal-Hanjani M; Pickering L
    Future Oncol; 2011 Jun; 7(6):727-36. PubMed ID: 21675836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents.
    Goodwin PJ; Stambolic V; Lemieux J; Chen BE; Parulekar WR; Gelmon KA; Hershman DL; Hobday TJ; Ligibel JA; Mayer IA; Pritchard KI; Whelan TJ; Rastogi P; Shepherd LE
    Breast Cancer Res Treat; 2011 Feb; 126(1):215-20. PubMed ID: 20976543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin--mode of action and clinical implications for diabetes and cancer.
    Pernicova I; Korbonits M
    Nat Rev Endocrinol; 2014 Mar; 10(3):143-56. PubMed ID: 24393785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular pathways: preclinical models and clinical trials with metformin in breast cancer.
    Thompson AM
    Clin Cancer Res; 2014 May; 20(10):2508-15. PubMed ID: 24682417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic mechanisms underlying antidiabetic drug metformin's chemopreventive effect against colorectal cancer.
    Jaromy M; Miller JD
    Eur J Pharmacol; 2021 Apr; 897():173956. PubMed ID: 33617821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes.
    Wiernsperger NF
    Diabetes Metab; 1999 Jun; 25(2):110-27. PubMed ID: 10443322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metformin, cancer and glucose metabolism.
    Salani B; Del Rio A; Marini C; Sambuceti G; Cordera R; Maggi D
    Endocr Relat Cancer; 2014; 21(6):R461-71. PubMed ID: 25273809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Metformin and AMPK: an old drug and a new enzyme in the context of metabolic syndrome].
    Santomauro Júnior AC; Ugolini MR; Santomauro AT; Souto RP
    Arq Bras Endocrinol Metabol; 2008 Feb; 52(1):120-5. PubMed ID: 18345405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena.
    Martin-Castillo B; Vazquez-Martin A; Oliveras-Ferraros C; Menendez JA
    Cell Cycle; 2010 Mar; 9(6):1057-64. PubMed ID: 20305377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metformin and prostate cancer stem cells: a novel therapeutic target.
    Mayer MJ; Klotz LH; Venkateswaran V
    Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):303-9. PubMed ID: 26215782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms.
    Wiernsperger NF; Bailey CJ
    Drugs; 1999; 58 Suppl 1():31-9; discussion 75-82. PubMed ID: 10576523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metformin: a diabetes drug for cancer, or a cancer drug for diabetics?
    Martin M; Marais R
    J Clin Oncol; 2012 Jul; 30(21):2698-700. PubMed ID: 22565000
    [No Abstract]   [Full Text] [Related]  

  • 33. Metformin diminishes the unfavourable impact of Nrf2 in breast cancer patients with type 2 diabetes.
    Urpilainen E; Kangaskokko J; Puistola U; Karihtala P
    Tumour Biol; 2019 Jan; 41(1):1010428318815413. PubMed ID: 30803422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Metformin - new data for an "old", but efficient, safe and reliable antidiabetic drug].
    Winkler G
    Orv Hetil; 2016 Jun; 157(23):882-91. PubMed ID: 27233831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polyphenols activate energy sensing network in insulin resistant models.
    Mutlur Krishnamoorthy R; Carani Venkatraman A
    Chem Biol Interact; 2017 Sep; 275():95-107. PubMed ID: 28751004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study.
    Karlsson HK; Hällsten K; Björnholm M; Tsuchida H; Chibalin AV; Virtanen KA; Heinonen OJ; Lönnqvist F; Nuutila P; Zierath JR
    Diabetes; 2005 May; 54(5):1459-67. PubMed ID: 15855334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Metformin and malignant neoplasms: a possible mechanism of antitumor action and prospects for use in practice].
    Kuznetsov KO; Safina ER; Gaimakova DV; Frolova YS; Oganesyan IY; Sadertdinova AG; Nazmieva KA; Islamgulov AH; Karimova AR; Galimova AM; Rizvanova EV
    Probl Endokrinol (Mosk); 2022 Jul; 68(5):45-55. PubMed ID: 36337018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does use of metformin protect against cancer in Type 2 diabetes mellitus?
    Bo S; Benso A; Durazzo M; Ghigo E
    J Endocrinol Invest; 2012 Feb; 35(2):231-5. PubMed ID: 22490993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Insulin-sensitizing agents: metformin and thiazolidinedione derivatives].
    Satoh J
    Nihon Rinsho; 2003 Jul; 61(7):1224-9. PubMed ID: 12877089
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic roles of AMPK and metformin in cancer cells.
    Choi YK; Park KG
    Mol Cells; 2013 Oct; 36(4):279-87. PubMed ID: 23794020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.